Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia

Leukemia and Lymphoma

Volumn 51, Issue 5, 2010, Pages 897-905

  Lee, Chin Cheng ^a,b   Lin, Che Pin ^c   Lee, Yueh Lun ^d   Wang, Giueng Chueng ^e   Cheng, Yuan Chih ^e   Liu, H Eugene ^b,e  

^a Shin Kong Wu Ho Su Hospital   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Acute myeloid leukemia; Apoptosis; Meisoindigo

Indexed keywords

ANTINEOPLASTIC AGENT; CD11B ANTIGEN; MEISOINDIGO; PROTEIN BAK; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; INDOLES; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; PROTO-ONCOGENE PROTEINS C-BCL-2; TELOMERASE; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 77951824361     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003672115     Document Type: Article

References (24)

1. Xiao Z, Qian L, Liu B, Hao Y. Meisoindigo for the treatment of chronic myelogenous leukaemia. Br J Haematol 2000;111:711-712.
2. Damiens E, Baratte B, Marie D, Eisenbrand G, Meijer L. Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 2001;20:3786-3797.
3. Suzuki K, Adachi R, Hirayama A, et al. Indirubin, a Chinese anti-leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells. Br J Haematol 2005;130:681-690.
4. Xiao Z, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 2002;43:1763-1768.
5. Wang Y, Liu B, Peng Y, Xiao Z. Studying of effects of meisoindigo on acute promyelocytic leukemia cell line NB4 in vitro. J Leuk Lymphoma 2005;14:136-139.
6. Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
7. Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A smallmolecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 2006;34:1480-1489.
8. Shimizu T, Takeda K. Induction of retinoic acid receptoralpha by granulocyte macrophage colony stimulating factor in human myeloid leukemia cell lines. Cancer Res 2000;60:4544-4549.
9. Liu L, Berletch JB, Green JG, Pate MS, Andrews LG, Tollefsbol TO. Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation. Mol Cancer Ther 2004;3:1003-1009.
10. Xu D, Popov N, Hou M, et al. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci USA 2001;98:3826-3831.
11. Cerone MA, Londono-Vallejo JA, Autexier C. Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells. Mol Cancer Ther 2006;5:1669-1675.
12. Nakamura M, Masutomi K, Kyo S, et al. Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy. Hum Gene Ther 2005;16:859-868.
13. Wu Y-L, Yin T, Sun Y, Wu W-L, Sun G-L. Meisoindigo in combination with imatinib accelerates apoptosis of K562 cells. Acad J Shanghai Sec Med Univ 2005;25:433-436.
14. Marko D, Schatzle S, Friedel A, et al. Inhibition of cyclindependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer 2001;84:283-289.
15. Perabo FG, Frossler C, Landwehrs G, et al. Indirubin-3'-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer. Anticancer Res 2006;26:2129-2135.
16. Cogswell JP, Cogswell PC, Kuehl WM, et al. Mechanism of c-myc regulation by c-Myb in different cell lineages. Mol Cell Biol 1993;13:2858-2869.
17. Xie Y, Liu Y, Ma C, et al. Indirubin-3'-oxime inhibits c-Jun. NH2-terminal kinase: anti-apoptotic effect in cerebellar granule neurons. Neurosci Lett 2004;367:355-359.
18. Nam S, Buettner R, Turkson J, et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 2005;102:5998-6003.
19. Sethi G, Ahn KS, Sandur SK, Lin X, Chaturvedi MM, Aggarwal BB. Indirubin enhances tumor necrosis factorinduced apoptosis through modulation of nuclear factorkappa B signaling pathway. J Biol Chem 2006;281:23425-23435.
20. Konnikova L, Simeone MC, Kruger MM, Kotecki M, Cochran BH. Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res 2005;65:6516-6520.
21. Nakatake M, Kakiuchi Y, Sasaki N, Murakami-Murofushi K, Yamada O. STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells. Cell Cycle 2007;6:1496-1501.
22. Xiao Z, Wang Y, Lu L, et al. Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro. Leuk Res 2006;30:54-59.
23. Mingxin Z, Yan L, Hongbo W, et al. The antitumor activity of meisoindigo against human colorectal cancer HT-29 cells in vitro and in vivo. J Chemother 2008;20:728-733.
24. Wee XK, Yeo WK, Zhang B, et al. Synthesis and evaluation of functionalized isoindigos as antiproliferative agents. Bioorg Med Chem 2009;17:7562-7571.